Publication: Risk of Secondary Progressive Multiple Sclerosis After Early Worsening of Disability
| dc.authorscopusid | 57865209700 | |
| dc.authorscopusid | 55028512500 | |
| dc.authorscopusid | 7006700571 | |
| dc.authorscopusid | 7005179252 | |
| dc.authorscopusid | 56549046700 | |
| dc.authorscopusid | 57222512447 | |
| dc.authorscopusid | 6602078414 | |
| dc.authorwosid | Patti, Francesco/C-3300-2011 | |
| dc.authorwosid | Eichau, Sara/Aaa-8145-2019 | |
| dc.authorwosid | Lugaresi, Alessandra/C-7743-2012 | |
| dc.authorwosid | Terzi̇, Murat/Aaa-1284-2021 | |
| dc.authorwosid | Lugaresi, Alessana/C-7743-2012 | |
| dc.authorwosid | Onofrj, Marco/K-7710-2016 | |
| dc.authorwosid | Soysal, Aysun/Aax-7696-2021 | |
| dc.contributor.author | Dzau, Winston | |
| dc.contributor.author | Sharmin, Sifat | |
| dc.contributor.author | Patti, Francesco | |
| dc.contributor.author | Izquierdo, Guillermo | |
| dc.contributor.author | Eichau, Sara | |
| dc.contributor.author | Prat, Alexandre | |
| dc.contributor.author | Kalincik, Tomas | |
| dc.contributor.authorID | Lugaresi, Alessana/0000-0003-2902-5589 | |
| dc.contributor.authorID | Onofrj, Marco/0000-0002-0480-2495 | |
| dc.contributor.authorID | Prat, Alexane/0000-0001-6188-0580 | |
| dc.date.accessioned | 2025-12-11T01:29:33Z | |
| dc.date.issued | 2023 | |
| dc.department | Ondokuz Mayıs Üniversitesi | en_US |
| dc.department-temp | [Kalincik, Tomas] Univ Melbourne, Dept Med, CORe, Melbourne, Vic 3050, Australia; [Dzau, Winston; Buzzard, Katherine; Kalincik, Tomas] Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, Parkville, Vic, Australia; [Dzau, Winston; Sharmin, Sifat; Kalincik, Tomas] Univ Melbourne, Dept Med, CORe, Melbourne, Vic, Australia; [Patti, Francesco] Univ Catania, Dept Surg & Med Sci & Adv Technol GF Ingrassia, Neurosci, Catania, Italy; [Patti, Francesco] Univ Catania, Multiple Sclerosis Ctr, Catania, Italy; [Izquierdo, Guillermo; Eichau, Sara] Hosp Univ Virgen Macarena, Dept Neurol, Seville, Andalucia, Spain; [Prat, Alexandre; Girard, Marc; Duquette, Pierre] CHUM, MS Ctr, Montreal, PQ, Canada; [Prat, Alexandre; Girard, Marc; Duquette, Pierre] Univ Montreal, Fac Med, Montreal, PQ, Canada; [Onofrj, Marco] Gabriele Annunzio Univ Chieti & Pescara, Dept Neurosci Imaging & Clin Sci, Dept Sci, Chieti, Italy; [Lugaresi, Alessandra] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy; [Lugaresi, Alessandra] IRCCS Ist Sci Neurol Bologna, UOSI Riabilitaz Sclerosi Multipla, Bologna, Italy; [Ozakbas, Serkan] Dokuz Eylul Univ, Fac Med, Izmir, Turkiye; [Gerlach, Oliver] Zuyderland Med Ctr, Dept Neurol, Sittard Geleen, Netherlands; [Gerlach, Oliver] Univ Maastricht, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Boz, Cavit] Karadeniz Tech Univ, Med Fac, Trabzon, Turkiye; [Duquette, Pierre] CIUSSS Ctr Ouest De Iile De Montreal, Dept Neurol, Montreal, PQ, Canada; [Terzi, Murat] Ondokuz Mayis Univ, Med Fac, Samsun, Turkiye; [Amato, Maria Pia] Univ Florence, Dept NEUROFARBA, Florence, Italy; [La Spitaleri, Daniele] Azienda Osped Rilievo Nazl & Alta Special San Gius, Dept Neurol, Avellino, Italy; [Ramo-Tello, Cristina] Hosp Badalona Germans Trias & Pujol, Dept Neurol, Badalona, Spain; [Maimone, Davide] Azienda Osped Rilievo Nazl & Alta Specializzaz Gar, UO Neurol, Catania, Sicilia, Italy; [Cartechini, Elisabetta] Azienda Sanit Unica Reg, UOC Neurol, Ancona, Italy; [Buzzard, Katherine; Skibina, Olga] Box Hill Hosp, Dept Neurol, Box Hill, Vic, Australia; [Buzzard, Katherine; Skibina, Olga] Monash Univ, Dept Med, Clayton, Vic, Australia; [Skibina, Olga; van der Walt, Anneke; Butzkueven, Helmut] The Alfred, Dept Neurol, Melbourne, Vic, Australia; [van der Walt, Anneke; Butzkueven, Helmut] Monash Univ, Cent Clin Sch, Clayton, Vic, Australia; [Iuliano, Gerardo] Azienda Osped Univ San Giovanni Dio & Ruggi Aragon, Dept Neurol, Salerno, Italy; [Soysal, Aysun] Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Dept Neurol, Istanbul, Turkiye | en_US |
| dc.description | Lugaresi, Alessana/0000-0003-2902-5589; Onofrj, Marco/0000-0002-0480-2495; Prat, Alexane/0000-0001-6188-0580; | en_US |
| dc.description.abstract | BackgroundWhether progression independent of relapse activity (PIRA) heralds earlier onset of secondary progressive multiple sclerosis (SPMS) and more rapid accumulation of disability during SPMS remains to be determined. We investigated the association between early PIRA, relapse-associated worsening (RAW) of disability and time to SPMS, subsequent disability progression and their response to therapy. MethodsThis observational cohort study included patients with relapsing-remitting multiple sclerosis (RRMS) from the MSBase international registry across 146 centres and 39 countries. Associations between the number of PIRA and RAW during early multiple sclerosis (MS) (the initial 5 years of MS onset) were analysed with respect to: time to SPMS using Cox proportional hazards models adjusted for disease characteristics; and disability progression during SPMS, calculated as the change of Multiple Sclerosis Severity Scores over time, using multivariable linear regression. Results10 692 patients met the inclusion criteria: 3125 (29%) were men and the mean MS onset age was 32.2 years. A higher number of early PIRA (HR=1.50, 95% CI 1.28 to 1.76, p<0.001) and RAW (HR=2.53, 95% CI 2.25 to 2.85, p<0.001) signalled a higher risk of SPMS. A higher proportion of early disease-modifying therapy exposure (per 10%) reduced the effect of early RAW (HR=0.94, 95% CI 0.89 to 1.00, p=0.041) but not PIRA (HR=0.97, 95% CI 0.91 to 1.05, p=0.49) on SPMS risk. No association between early PIRA/RAW and disability progression during SPMS was found. ConclusionsEarly disability increase during RRMS is associated with a greater risk of SPMS but not the rate of disability progression during SPMS. The deterioration associated with early relapses represents a potentially treatable risk factor of SPMS. | en_US |
| dc.description.sponsorship | Merck; Biogen; Novartis; Bayer-Schering; Sanofi-Genzyme; Teva | en_US |
| dc.description.sponsorship | TK and WD had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The MSBase Foundation is a not-for-profit organization that receives support from Merck, Biogen, Novartis, Bayer-Schering, Sanofi-Genzyme and Teva. All aspects of the study were completed independent and separate from the MSBase funders - including design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. We thank the MSBase Operations Team, Ms Charlotte Sartori, Ms Pamela Farr, Ms Rein Moore, Mr Dusko Stupar, Ms Cynthia Tang and Ms Sonya Smirnova. Further acknowledgements found in Appendix A. | en_US |
| dc.description.woscitationindex | Science Citation Index Expanded | |
| dc.identifier.doi | 10.1136/jnnp-2023-331748 | |
| dc.identifier.endpage | 991 | en_US |
| dc.identifier.issn | 0022-3050 | |
| dc.identifier.issn | 1468-330X | |
| dc.identifier.issue | 12 | en_US |
| dc.identifier.pmid | 37414538 | |
| dc.identifier.scopus | 2-s2.0-85166407723 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | 984 | en_US |
| dc.identifier.uri | https://doi.org/10.1136/jnnp-2023-331748 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12712/44061 | |
| dc.identifier.volume | 94 | en_US |
| dc.identifier.wos | WOS:001031822500001 | |
| dc.identifier.wosquality | Q1 | |
| dc.language.iso | en | en_US |
| dc.publisher | BMJ Publishing Group | en_US |
| dc.relation.ispartof | Journal of Neurology Neurosurgery and Psychiatry | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Multiple Sclerosis | en_US |
| dc.title | Risk of Secondary Progressive Multiple Sclerosis After Early Worsening of Disability | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication |
